- Home
- / Satsuma Pharmaceuticals
Satsuma Pharmaceuticals
Stock Price
$1.1
2023-06-09
Market Capitalization
$36.8 M
2023-06-09
Satsuma Pharmaceuticals Summary
Company Summary
- Overview
- Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.
- Type
- Public
- Status
- Active
- Founded
- 2016
- HQ
- South San Francisco, CA, US | view all locations
- Website
- http://www.satsumarx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Shannon Strom, Vice President, Head of Regulatory Affairs
Robert Schultz, Senior Vice President and Head of Chemistry, Manufacturing and Controls
Mic Iwashima, Vice President & Head of Operations
Operating MetricsView all
Drugs in Development
37
Aug, 2019
Patents (US)
6
Aug, 2019
Patents (Foreign)
9
Aug, 2019
LocationsView all
2 locations detected
South San Francisco, CA HQ
United States
400 Oyster Point Blvd #221
Durham, NC
United States
4819 Emperor Blvd #340
Satsuma Pharmaceuticals Financials
Summary Financials
- Net income (Q1, 2023)
- ($10.3M)
- Cash (Q1, 2023)
- $19.5M
- EBIT (Q1, 2023)
- ($10.8M)
- Enterprise value
- $17.5M